Medicover AB (ST:MCOVB) reported first-quarter results showing adjusted EBITDA of €104.6 million, roughly 6% above analyst estimates, and an adjusted EBITDA margin of 16.8%.
Group revenue for the quarter was €624.2 million, an 8.0% increase versus the prior year and marginally ahead of the consensus figure of €623.0 million. Organic growth for the period was 10.3%, with a 3.3% drag from currency movements and an additional €19.8 million contributed by acquisitions.
Net profit reached €20.6 million, a 9.9% improvement year-over-year and 11.3% ahead of the €18.5 million consensus. The company also reported an improved leverage position, with net debt to adjusted EBITDA falling to 2.9 times from 3.1 times at the close of fiscal 2025.
Healthcare Services performance
Revenue in the Healthcare Services division increased 7.2% to €431.7 million, with organic growth of 11.8%. The division saw a 6.8% contribution from pricing. Management highlighted scaling in Poland’s sports and wellness operations, as well as improved hospital performance in India and Romania. A continuing shift toward fee-for-service revenue supported results - fee-for-service accounted for 54% of divisional sales and grew 14.8% during the quarter.
Membership across the group was 1.52 million, a year-over-year decline attributed to the prior exit from Hungary. India delivered 14.3% growth, supported by capacity additions including a 550-bed hospital that opened in Hyderabad during the quarter. EBITDA for Healthcare Services rose 18.1% to €74.3 million, with the division margin expanding to 17.2%. The company reported that hospitals opened in India in the past two years recorded start-up losses amounting to €3.8 million.
Diagnostics Services trends
Diagnostics Services revenue advanced 9.9% to €200.3 million, comprising 7.2% organic growth and a 3.4% price increase. Fee-for-service revenue continued to dominate the segment, representing 72% of sales and rising 14.0%. Test volume climbed 9.5% to 39.8 million, with 8.7% of that increase related to an acquisition completed in the second quarter of 2025.
The diagnostics business faced operational headwinds including power supply issues in Ukraine and weather-related disruptions in other markets. Despite these challenges, segment EBITDA increased 16.2% to €41.7 million, producing a margin of 20.8%.
Overall, Medicover’s quarter combined double-digit organic top-line growth with margin expansion across both core divisions, improving profitability and lowering leverage. The reported figures reflect contributions from pricing, acquired revenue and network capacity expansions in targeted markets.